Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials
Authors
Keywords
-
Journal
Diabetes & Metabolic Syndrome-Clinical Research & Reviews
Volume 16, Issue 11, Pages 102640
Publisher
Elsevier BV
Online
2022-10-15
DOI
10.1016/j.dsx.2022.102640
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials
- (2022) Junaid Iqbal et al. Obesity Reviews
- The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
- (2022) Ali A Rizvi et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression
- (2021) Timotius Ivan Hariyanto et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
- (2021) Kenichi Furihata et al. DIABETES OBESITY & METABOLISM
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
- (2021) Akshaya Srikanth Bhagavathula et al. Pharmaceuticals
- Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
- (2020) Juan Pablo Frias et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
- (2020) Laurie L. Baggio et al. Molecular Metabolism
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- The incretin system in healthy humans: The role of GIP and GLP-1
- (2019) Jens Juul Holst METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Definition, Classification and Diagnosis of Diabetes Mellitus
- (2019) Astrid Petersmann et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Recent advances of GIP and future horizons
- (2019) Jens Juul Holst et al. PEPTIDES
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
- (2013) Mikkel B. Christensen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
- (2012) Su-Jin Kim et al. PLoS One
- Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
- (2011) M. Christensen et al. DIABETES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search